Metraipolis › archive › dc_dff9f8bf7b3d
Critical analysis of withdrawn drug applications in marketing authorization procedures of the European Medicines Agency (EMA) 2006-2024 — Europe PMC PMID:42171747
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42171747
- DOI
- 10.1007/s00210-[numero omesso]-1
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T09:14:28.711Z
- SHA-256 of the archived text
2f41d0d7314bb9e708678af016be5df037b6b8a401837c7be9eb155452e3c388- Stable URL of this page
https://metraipolis.com/documento/dc_dff9f8bf7b3d
How to cite
Critical analysis of withdrawn drug applications in marketing authorization procedures of the European Medicines Agency (EMA) 2006-2024 — Europe PMC PMID:42171747 — Europe PMC (en), https://europepmc.org/article/MED/42171747 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dff9f8bf7b3d (Metraipolis archive dc_dff9f8bf7b3d, sha256 2f41d0d7314bb9e708678af016be5df037b6b8a401837c7be9eb155452e3c388)
BibTeX
@misc{dcdff9f8bf7b3d,
title = {Critical analysis of withdrawn drug applications in marketing authorization procedures of the European Medicines Agency (EMA) 2006-2024 — Europe PMC PMID:42171747},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42171747},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dff9f8bf7b3d; sha256 2f41d0d7314bb9e708678af016be5df037b6b8a401837c7be9eb155452e3c388},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42171747. Agents can read the archived copy with the MCP tool read_document.